CytomX shares plummet as Amgen-partnered cancer drug yields jumbled Phase 1 data
CytomX and Amgen’s T cell engager showed mixed efficacy signals in an early trial in advanced solid tumors, sending the biotech’s shares down 37% even …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
